title: Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team.
abstract: BACKGROUND
  In patients with the acquired immunodeficiency syndrome (AIDS), toxoplasmic encephalitis is usually a presumptive diagnosis based on the clinical manifestations, a positive antitoxoplasma-antibody titer, and characteristic neuroradiologic abnormalities. A response to specific therapy helps to confirm the diagnosis, but it is unclear how rapid the response should be. We studied the course of patients treated for acute toxoplasmic encephalitis and evaluated objective clinical criteria for this empirical diagnosis.
  
  
  METHODS
  A quantifiable neurologic assessment was used prospectively to evaluate the clinical outcome of patients with AIDS and toxoplasmic encephalitis who were treated with oral clindamycin (600 mg four times a day) and pyrimethamine (75 mg every day) for six weeks.
  
  
  RESULTS
  Thirty-five of 49 patients (71 percent) responded to therapy, and 30 of these (86 percent) had improvement by day 7. Thirty-two of those with a response (91 percent) improved with respect to at least half of their base-line abnormalities by day 14. Improvement in neurologic abnormalities within 7 to 14 days after the start of therapy was strongly associated with the neurologic response at 6 weeks. The four patients in whom treatment failed and the two patients with lymphoma had progressing neurologic abnormalities or new abnormalities during the first 12 days of therapy. Nonlocalizing abnormalities (headache and seizure) improved regardless of the clinical outcome.
  
  
  CONCLUSIONS
  Oral clindamycin and pyrimethamine are an effective treatment for toxoplasmic encephalitis. Patients who have early neurologic deterioration despite treatment or who do not improve neurologically after 10 to 14 days of appropriate antitoxoplasma therapy should be considered candidates for brain biopsy.
authors.affiliation: Division of Infectious Diseases, State University of New York at Stony Brook 11794.
authors.forename: B J
authors.initials: BJ
authors.lastname: Luft
authors.forename: R
authors.initials: R
authors.lastname: Hafner
authors.forename: A H
authors.initials: AH
authors.lastname: Korzun
authors.forename: C
authors.initials: C
authors.lastname: Leport
authors.forename: D
authors.initials: D
authors.lastname: Antoniskis
authors.forename: E M
authors.initials: EM
authors.lastname: Bosler
authors.forename: D D
authors.initials: DD
authors.lastname: Bourland
authors.forename: R
authors.initials: R
authors.lastname: Uttamchandani
authors.forename: J
authors.initials: J
authors.lastname: Fuhrer
authors.forename: J
authors.initials: J
authors.lastname: Jacobson
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000208:Acute Disease; D000328:Adult; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004660:Encephalitis / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology; D005260:Female; D006801:Humans; D008297:Male; D009460:Neurologic Examination; D011379:Prognosis; D011446:Prospective Studies; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D014123:Toxoplasmosis / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D002981:Clindamycin; D011739:Pyrimethamine